At present, the research of PPAR agents on ocular diseases remains limited, with most studies focusing on in-vitro and animal experiments, highlighting a paucity of data on the safety of topical PPAR agents in corneal diseases, However, the clinical application of systemic PPAR agents, notably the PPARα agonists belonging to the fibrates class such as fenofibrate and PPARγ agonists from the thiazolidinedione (TZD) class such as rosiglitazone, are well-validated in the treatment of dyslipidaemia and diabetes, respectively, with an established safety profile [19, 20]. The gene discussed is PPARA; the disease is diabetes mellitus.